


Emily DiMango, MD Asthma II

Director

John Edsall/John Wood Asthma
Center

Columbia University Medical Center

Figure 1
Asthma Prevalence, 1980-2000




* Gap between 1995-1996 and 1997 indicates a break in trend due to the redesign of the 1997 NHIS.
Source: Data extracted from Akinbami and Schoendorf. *Pediatrics*. 2002.

Asthma in the US


- 6% of the population (17 million)
- Most common cause of hospitalization among children
- Higher prevalence in some areas
- 5,000 deaths per year.
- Undertreated

Comparison of Asthma Hospitalization Rates in Children Aged 0-14 in the U.S., NYS and NYC, 1999



Asthma Definition


- Chronic inflammatory disorder of the airways
- Usually associated with atopy (extrinsic, intrinsic)
- Obstruction to airflow which is reversible (either spontaneously or with use of medications)
- Airway hyperresponsiveness and narrowing in response to a variety of stimuli




Busse, W, NEJM 2001; 344: 5

Asthma: A Lung Disease with Airway

- ➔ Obstruction (at least partially reversible)
- ➔ Hyperreactivity
- ➔ Inflammation




**Normal
Bronchiole**




Asthma


Airway Inflammatory Changes



Asthma Triggers




Airway inflammation - Early and late Response



Viral Respiratory Infections


Hospital admissions for asthma correlate with virus isolation peaks and school terms



Adapted with permission from Johnston SL et al. *Am J Respir Crit Care Med.* 1996;154:654. Official Journal of the American Thoracic Society. ©American Lung Association.

Early and Late Asthmatic Response Following Antigen Challenge²⁴

12-patient, 2-period crossover study



EAR = early asthmatic response; LAR = late asthmatic response

²⁴Data on file at Merck & Co., Inc.: DA-SNG14.

Methods For Measuring Airway Caliber




Maximum PEFR
airflow achieved

Home




FVC, FEV₁
FEF_{25%-75%}

Office/Clinic




Airway
Resistance

Clinic/Laboratory






FEV = 4.0
FVC = 5.0
% = 80



FEV = 1.3
FVC = 3.1
% = 42

$$\text{FVC} = \text{TLC} - \text{RV}$$







Diagnostic Criteria For Asthma

- Cough, dyspnea, wheeze, chest tightness
- Waxing and waning symptoms
- Airway hyperresponsiveness (narrowing), to naturally occurring stimuli
- Heightened airway reactivity – exacerbations upon exposure to stimuli
- Episodic airflow limitation in response to antigenic triggers.

Physiologic features of asthma

- Reversible airflow limitation with a significant ($> 12\%$) change in FEV₁ in response to inhaled bronchodilator.
- response to bronchoprovocation testing - challenge with agent which provokes bronchial narrowing (decrease of 20% in FEV₁) in sensitive individuals.





Asthma exacerbation

- Asthma trigger leads to increase in airway inflammation and bronchoconstriction – narrowing of airway lumen
- Increased resistance to airflow
- Reduction in FEV₁, PEF_R
- Will reverse either spontaneously (eventually) or with use of medication

Contributing Factors to Asthma Exacerbation

- Poorly controlled airway inflammation
- Cold air
- Exercise
- Upper respiratory tract infection
- sinusitis, rhinitis, GERD
- First or second hand tobacco smoke
- environmental allergens – indoor and outdoor

Gas exchange abnormalities in acute asthma exacerbation

- V/Q mismatch leads to hypoxemia
- Increased ventilatory drive leads to reduction in pCO₂.
- As severity of airflow obstruction increases, pCO₂ “pseudo-normalizes” then becomes elevated as respiratory muscle fatigue develops.

Hemodynamic changes during acute asthma

- Pulsus paradoxus correlates with level of airflow obstruction
- Cardiac output normal to increased
- RV strain with p-pulmonale on EKG

Physical Examination

Physical examination of the chest may be normal.

- ➔ Wheezing or prolonged force expiration
 - may not correlate with obstruction
- ➔ Hyperinflation of the lungs
- ➔ Use of accessory muscles

Pathologic targets in asthma

- Smooth muscle
- Airway inflammatory cells
- Inflammatory cytokines
- Bronchial epithelium
- Bronchial blood vessels (anti-VLA-4)

Reliever vs. controller medications

Reliever medications

- Short acting bronchodilators

Controller medications

- Inhaled corticosteroids
- Leukotriene modifiers
- Theophyllin
- Cromolyn
- Long acting bronchodilators

Glucocorticoids (Steroids)

- Most effective anti-inflammatory agent for treatment of persistent asthma
- Reduce influx of inflammatory cells into the airways (eosinophils, lymphs)
- Reduce production of pro-inflammatory cytokines by airway epithelial cells
- Reduce airway edema and mucus production
- May reduce airway remodeling

Inhaled glucocorticoids

- First line therapy for all but very mild asthma
- Early initiation of therapy may preserve lung function
- Many different preparations with differences in systemic absorption due to first pass metabolism


Side effects of inhaled steroids

- Thrush and dysphonia are local effects
- Systemic effects: growth retardation, adrenal suppression, osteoporosis, cataracts, acne, skin fragility with high doses.
- Biochemical markers of systemic effects are present with use of high dose


Concerns regarding use of inhaled glucocorticoids

- Adrenal suppression
- Bone demineralization
- Cataracts
- Growth retardation in children
- ?related to dose and duration of therapy



SHORT TERM EFFICACY OF INHALED STEROIDS



Early initiation of inhaled corticosteroids preserves lung function



Haahtela, T. et al. N Engl J Med 1994;331:700-705




Leukotrienes in Asthma

- Chemoattractant for eosinophils
- Smooth muscle contraction
- Vascular permeability
- Enhanced mucus production
- Can block by leukotriene synthesis inhibitors or receptor antagonists (oral agents)

SINGULAIR® vs. Beclomethasone

Mean FEV₁ Response (Study 2)



In this study, patients benefited from:

- Mandatory spacer device
- Enforced compliance (~90%)
- Rigorous monitoring


β_2 -agonists (Albuterol)

- Bind to β_2 receptors on airway smooth muscle cells, cause relaxation of muscle and bronchial dilatation
- Most effective bronchodilators available, short term relief of bronchoconstriction
- Rapid onset of activity; duration of action 3-6 hours.
- “rescue” therapy for symptom relief
- no effect on chronic inflammation
- Regularly schedule vs. prn use

Side effects of β_2 agonists

- Due to non-airway β_2 activity: muscle tremor, metabolic
- Due to overlap β_1 activity: tachycardia, arrhythmia, hypokalemia
- Regular use related to higher mortality and morbidity – may be related to polymorphisms in β_2 receptor
- Possible tachyphylaxis – mild downregulation of cell surface receptor number and desensitization of the receptor to drug.

Effect of polymorphisms at the amino acid residue 16 locus of the B₂ adrenergic receptor




Other potential explanations

- Use of b-agonists is a marker of disease severity
- b-agonists have adverse effects on extra-pulmonary organ systems
- b-agonists may make asthma worse (by increasing airway hyperresponsiveness)
- Over reliance on b-agonists may mask severity of disease and delay use of additional modes of therapy to address underlying airway inflammation

Long acting beta agonists


- Inhaled salmeterol and formoterol
- Duration of action 12 hours
- Delayed onset of action (30 minutes)
- Efficacious in moderate to severe asthma
- Useful for nocturnal asthma
- Not monotherapy; ie add on to anti-inflammatory therapy to reduce need for inhaled steroids
- Allow reduction of inhaled steroid dose
- **New black box warning: Increased mortality and serious events in patients taking long acting beta agonists**

Effect of Salmeterol added to low dose inhaled steroids



Adapted from J. Murray, *Allergy and Asthma Proc.* 1999;20:173-180.

Occurrence of asthma-related deaths by phase and study year



Nelson, H. S. et al. Chest 2006;129:15-26

Cromolyn agents for asthma (Intal, Nedocromil)

- Stabilize mast cells, reduce release of proinflammatory agents.
- Useful for exercise induced asthma, but not as effective as beta agonists
- Extremely safe

Anticholinergic Drugs (Ipratropium Bromide)

- Block muscarinic receptors on airway smooth muscle
- Inhibit bronchoconstriction caused by cholinergic nerves, no action against the direct effects of mediators on airway smooth muscle
- slower onset of action; reduced efficacy compared with β_2 agonists
- Additive when used in combination with β_2 agonists


theophylline

- Phosphodiesterase inhibitor – increases intracellular cAMP in inflammatory cells
- Anti-inflammatory and bronchodilator properties
- Additive therapy when not adequately controlled with inhaled steroids
- Therapeutic ratio limits use; better agents available; more selective agents under study

Exercise induced asthma (EIA)

- Occurs in 80-90% of patients with chronic asthma
- 30-40% of athletes with allergies
- 10% of healthy athletes without allergies or asthma
- 17% in Winter Olympic athletes, 16% in summer Olympics
- Vigorous physical activity with associated hyperventilation of cool, dry air triggers acute airway narrowing, classically at the end of exercise when airways rewarm and rehumidify
- Higher prevalence reported among athletes than in general healthy population


FALL IN FEV₁ RELATED TO EXERCISE



Biologics in treatment of asthma

- Anti-IL5 tested, not efficacious
- Anti-IgE is first compound commercially available.
- Expensive
- Subcutaneous injection
- ? Duration of therapy

Effect of anti-IgE on corticosteroid dose in severe asthmatics




Milgrom, H. et al. N Engl J Med 1999;341:1966-1973

Treatment of acute asthma exacerbation

- High dose β_2 agonist (inhaled, SQ, IV)
- Nebulized anticholinergics
- epinephrine
- Corticosteroids
- Oxygen
- Mechanical ventilation

Corticosteroids in the Treatment of Acute Asthma



Ref: Fanta, et al: Am J Med 1983.

Assessment of asthma severity during office visits

- Nocturnal awakenings from asthma symptoms over the past month.
- Days per week with symptoms
- Need for rescue bronchodilators
- Activity limitation because of asthma

NAEPP (2002) Guidelines for Asthma Severity classification

- Mild intermittent: symptoms < 2x/week, nocturnal symptoms < 2x/month, normal FEV1
- Mild persistent: symptoms 3-6x/week, 3-4 awakenings/month, normal FEV1
- Moderate persistent: daily symptoms, >5 nocturnal awakenings/month, FEV1 60-80%
- Severe persistent: continual symptoms, FEV1 < 60%

Long term control of asthma

- **Symptoms occurring more than twice per week is an indication for *daily* anti-inflammatory therapy.**
- Step up anti-inflammatory therapy based on need for bronchodilators and frequency of symptoms
- Can use leukotriene modifiers and long acting b-agonist as steroid sparing agents.

Asthma which is difficult to control

- Observe inhaler technique
- Other diagnoses
- Adherence to regimen
- Reflux or sinusitis present
- Sensitivity to medication (NSAIDS, food additives)
- Abuse of OTC inhalers
- Environmental stimulus – mold, smoking

Future Goals

- Pharmacogenetics
- Identification of genes responsible for disease
- Biologics (monoclonal blocking antibodies)
- Th2/Th1 balance - vaccines
- Reduce morbidity and mortality in inner city minorities